GLP-1 zvinodhaka seOzempic uye Wegovy
- Tsvagiridzo nyowani yakapihwa kuAmerican Heart Association Scientific Sessions inoratidza kuti semaglutide, iyo inoshanda muOzempic neWegovy, ine zvakakosha pahutano hwemoyo.
- Humbowo hwakaratidza kuti varwere vanorapwa neGLP-1 vaive nenjodzi yakadzikira yekurova kwemoyo uye sitiroko.
- Zviratidzo zvekushaya simba kwemoyo zvakare zvakagadziridzwa panguva yekurapa ne semaglutide.
Semaglutide, mushonga weGLP-1 wakatanga kunyorerwa chirwere cheshuga uyezve kufutisa, unogona kukurumidza kurapa chirwere chemoyo.
Mukupera kwesvondo, kuAmerican Heart Association Scientific Sessions 2023, vatsvakurudzi vakapa humbowo hunogutsa hwekushanda kwe semaglutide (inotengeswa pasi pezita rechiratidzo Wegovy neOzempic) mukudzivirira kurohwa kwemoyo nekurohwa.
Imwe tsvagiridzo yakaratidzawo kuti mushonga uyu unogona kushandiswa kuvandudza zviratidzo kune varwere vane moyo kutadza, kunyanya kutadza kwemoyo neyakachengetwa ejection chikamu (HFpEF).
Zvakatorwa pamwe chete, zvidzidzo zviviri izvi, izvo zvakazobudiswa mumagazini makuru ezvokurapa, zvinoratidza chivimbiso che semaglutide senzira yekurapa kune varwere vari pangozi yezviitiko zvakakomba zvemwoyo uye kukanganisa kwemoyo.
Muzviitiko zvese izvi, tsvagiridzo iyi yakatsigirwa naNovo Nordisk, mugadziri weOzempic uye Wegovy.
Ko semaglutide ine yemoyo inobatsira here?
Ongororo yakapihwa vhiki ino uye yakabudiswa panguva imwe chete muNew England Journal of Medicine yakaongorora mhedzisiro kubva ku SELECT kuedza, multicenter, double-blind, randomized, placebo-controlled controlled trial yakaitwa naNovo Nordisk kuti idzidze migumisiro yemwoyo kune varwere vanobatwa semaglutide. zvinopesana ne placebo.
Tsvagiridzo yakapihwa kupera kwesvondo rino inotarisa huwandu hwevanhu vanofa, kusiri kuuraya kurwisa kwemoyo uye sitiroko isingaurayi muvarwere vasina chirwere cheshuga. Mushonga wacho wakamboratidzwa kuderedza zviitiko izvi kune varwere vane chirwere cheshuga chechipiri.
Kuedzwa uku ndiko kukurusa kwakamboitwa nekambani yeDenmark inogadzira mishonga uye kwakabata vanhu vanopfuura zviuru gumi nezvinomwe munyika makumi mana neimwe.
Chidzidzo ichi chakaitwa pakati paGumiguru 2018 naKurume 2021 uye chakatora makore mashanu, kusanganisira nguva yekutevera murwere.
Munguva yekutongwa, hafu yevatori vechikamu yakagamuchira semaglutide (chiyero che 2,4 mg kamwe pavhiki), asi imwe hafu yakagamuchira placebo. Varwere mukutongwa vakanga vakwegura 45 kana kupfuura, vaiva neBMI ye27 kana kupfuura, uye vaiva nechirwere chemwoyo chisati chavapo. Vaifanira kunge vasina nhoroondo yechirwere cheshuga.
Varwere vakatora semaglutide vaiva nengozi yavo yezvinetso zvakakomba zvemwoyo zvakaderedzwa pasi rose: njodzi yakawanda yechiitiko chemwoyo yakaderera ne20%, njodzi yekurwadziwa kwemoyo ne28%, uye njodzi yekurohwa ne7%.
Paivawo nezvimwe zvinobatsira. Iro semaglutide boka rakarasikirwa ne9,39% yehuremu hwemuviri wavo, zvichienzaniswa nechepasi pe1% yeboka re placebo. Vakaonawo kuvandudzwa muropa ravo, cholesterol mazinga uye HbA1c mazinga.
Novo Nordisk yakamboburitsa dhata rekutanga pane iyo SELECT miedzo yemhedzisiro muna Nyamavhuvhu.
Semaglutide inobatsira here nekushaya moyo?
Tsvagiridzo yakaburitswa munaNovember 12 mukati Circulationthe flagship publication yeAmerican Heart Association, yakadzidza semaglutide kurapwa kuti ivandudze zviratidzo zvekukundikana kwemoyo nekuchengetedzwa kwejection fraction, iyo inowanzozivikanwa yekushaya mwoyo.
Vatsvakurudzi vakatarisa matanho akasiyana-siyana munzvimbo dzakadai sehupenyu hwehupenyu, zvigaro zvemagariro evanhu, uye zvikanganiso zvemuviri vachishandisa Kansas City Cardiomyopathy Questionnaire (KCCQ), iyo inopa mucherechedzo wezviratidzo zvekukundikana kwemoyo zvichibva pane zvakatevedzana zvezvikonzero.
Iyo 52-vhiki, randomized, kaviri-mapofu, placebo-inodzorwa muedzo waisanganisira 529 vatori vechikamu. Hafu yevatori vechikamu yakagamuchira jekiseni yevhiki nevhiki ye2,4 mg ye semaglutide, asi imwe hafu yakagamuchira placebo. Varwere vaifanira kuve nekufutisa pamwe nenhoroondo yakanyorwa yeHFpEF.
Vanhu vanobatwa ne semaglutide vakawana kuvandudzwa kukuru kwezviratidzo zvekukundikana kwemoyo, zvinoratidzirwa nekuvandudzwa kweKCCQ chikamu, kuderera kukuru kwehuremu hwemuviri, uye kuvandudzwa kwekushaya simba uye kurovedza muviri basa.
“Iko zvino tave panhongonya yedata iri iro rinotiratidza kuti kufutisa ndiko kuri kukonzera matambudziko aya. Kuti tibudirire kugadzirisa matambudziko aya, tinofanira kugadzirisa kufutisa, tinoda kunanga kufutisa, "Dr. Mikhail Kosiborod, chiremba wemwoyo, mutevedzeri wemutungamiri wekutsvakurudza paSaint Luke's Health System uye munyori mukuru wekudzidza. kudzidza, akaudza Healthline.
Mhedzisiro yacho inovaka pane zvakambowanikwa zvakaburitswa kutanga kwegore rino.
HFpEF inoreva zvakasiyana-siyana zvekutadza kwemoyo umo moyo wakaoma zvakanyanya kuti uzadze zvakanaka.
Kunyangwe kutadza kwemoyo uye kufutisa kwakasiyana mamiriro ehutano, anowanzoitika pamwe chete. Wongororo mu JAMA Pakutanga gore rino, zvakaonekwa kuti vanhu vane uremu hwepamusoro kana kuti vakafutisa BMIs vaive nenjodzi yakanyanya yeHFpEF.
Dr. Lynne Warner Stevenson, purofesa wemishonga yemwoyo paVanderbilt uye mutungamiriri wepurogiramu yavo ye cardiomyopathy, uyo akanga asina kubatanidzwa nekutsvakurudza, akaudza Healthline:
“Ndiwo mapeji esaisai aya akasimukira kuedza kutsvaga nzira dzekudzikisa hurwere nerufu rwandinoona seVenn diagram yechirwere chinova kufutisa, chirwere cheshuga nemoyo. kutadza nechikamu chejection chakachengetedzwa.
GLP-1 mishonga inobatsira kurapa chirwere cheshuga, kufutisa uye chirwere chemoyo
"Ini ndinofunga munhu wese ari kufara uye isu tese tanga takamirira, kunyanya kuyedza SELECT, uye ndinofunga inhau dzakanaka," akadaro Dr. Sun Kim, purofesa wezvemishonga mu endocrinology paThe University kubva kuStanford, akaudza Healthline. Haana kutora chikamu mukutsvagisa.
"Endocrinologists vane hukama hwakasiyana hwekirasi iyi yemishonga nekuti yakatanga kubvumidzwa kurapwa kwerudzi rwe2 chirwere cheshuga uye chekutonga shuga muropa, asi vakaratidzwa kuti vane zvimwe zvakawanda zvinobatsira," akadaro.
Vanyori vechikamu chinoperekedza mu NEJM akanyora kuti: “Tava munguva itsva yekurapa kufutisa uye njodzi yeCardiometabolic nekuwedzera kuri kuita sarudzo. Iyo SELECT muyedzo inopa humbowo hwekuvandudzwa kwechirwere chemoyo mhedzisiro neGLP-1 receptor agonist mukushaikwa kwechirwere cheshuga.
Zvisinei, vakacherechedzawo kuti mari uye kuwanikwa kwe semaglutide inoramba iri zvipingamupinyi zvakakosha kuvanhu vakawanda.
Novo Nordisk yakaisa chikumbiro chekuvandudza label yeWegovy kuti ibatanidze chiratidzo chekudzikisa zviitiko zvakakomba zvemoyo. Iyo FDA yakapa iyo yekutanga ongororo yekuwedzera iyi yekuwedzera mushonga mutsva.
Kambani iyi yakapa Healthline chirevo chinotevera kubva kuna Dr. Michelle Skinner, PharmD, cardiorenal therapy area leader, zvekurapa kuNovo Nordisk:
"Mhedzisiro yakakwana yeSARU yakaunzwa kuAHA chiratidzo chekuchinja musainzi yekufutisa. Tinotarisira kushanda nevatongi pamatanho anotevera ekupa iyi sarudzo kune vanhu vane uremu hwepamusoro kana kuti vakafutisa uye vatapi vehutano vanobatana mukutarisira kwavo.
Izvo zvakakosha
Humbowo huri kubuda hunoratidza kuti semaglutide inogona kunge iine mabhenefiti akakosha pahutano hwemoyo uye kutadza kwemoyo.
Zvinoenderana nedata kubva kuNovo Nordisk's SELECT muyedzo, varwere vanobatwa nesemaglutide vaive ne20% yakaderedzwa njodzi yese yezvakakomba zvakashata zvemoyo zviitiko zvichienzaniswa ne placebo.
Muedzo wakasiyana wakaratidzawo kuti mushonga uyu waishanda mukurapa zviratidzo zvekutadza kwemoyo nechikamu chakachengetedzwa chejection.
VERENGA ZVAKAWANDA VERENGA ZVAKAWANDA VERENGA ZVAKAWANDA VERENGA ZVAKAWANDA VERENGA ZVAKAWANDA VERENGA ZVAKAWANDA